STTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-10-31), Shattuck Labs's share price is $1.315. Shattuck Labs's Book Value per Share for the quarter that ended in Jun. 2024 was $2.32. Hence, Shattuck Labs's PB Ratio of today is 0.57.
Good Sign:
Shattuck Labs Inc stock PB Ratio (=0.58) is close to 1-year low of 0.53
The historical rank and industry rank for Shattuck Labs's PB Ratio or its related term are showing as below:
During the past 6 years, Shattuck Labs's highest PB Ratio was 7.06. The lowest was 0.43. And the median was 1.04.
During the past 12 months, Shattuck Labs's average Book Value Per Share Growth Rate was -28.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -25.50% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Shattuck Labs was -25.50% per year. The lowest was -25.50% per year. And the median was -25.50% per year.
The historical data trend for Shattuck Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shattuck Labs Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
PB Ratio | Get a 7-Day Free Trial | - | 7.06 | 1.33 | 0.55 | 2.33 |
Shattuck Labs Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
PB Ratio | Get a 7-Day Free Trial | 0.96 | 0.57 | 2.33 | 3.30 | 1.67 |
For the Biotechnology subindustry, Shattuck Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Shattuck Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Shattuck Labs's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Jun. 2024) |
= | 1.315 | / | 2.318 | |
= | 0.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Shattuck Labs (NAS:STTK) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Shattuck Labs's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Tyler Brous | director | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Taylor Schreiber | director, officer: Chief Executive Officer | 100 EUROPA DRIVE, CHAPEL HILL NC 27517 |
Stephen Stout | officer: See Remarks | C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701 |
Andrew R Neill | officer: See Remarks | 1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703 |
George Golumbeski | director | C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Abhinav A. Shukla | officer: Chief Technical Officer | 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701 |
Carrie Brownstein | director | 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701 |
Erin Ator Thomson | officer: General Counsel | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Josiah Hornblower | director, 10 percent owner, officer: Chairman | 3317 BOWMAN AVE, AUSTIN TX 78703 |
Redmile Group, Llc | director, 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Neil W Gibson | director | C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
Helen M Boudreau | director | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Arundathy N. Pandite | officer: Chief Medical Officer | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Victor Stone | director | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Casi Deyoung | officer: Chief Business Officer | C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 07-01-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 07-30-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 11-09-2023
By GuruFocus Research • 02-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.